You are here

Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R44AR075469-02
Agency Tracking Number: R44AR075469
Amount: $992,935.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIAMS
Solicitation Number: PA18-574
Solicitation Year: 2018
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-07-15
Award End Date (Contract End Date): 2022-11-30
Small Business Information
Los Angeles, CA 90025-1596
United States
DUNS: 081337056
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (303) 506-1681
Business Contact
Phone: (303) 506-1681
Research Institution

MyoGene Bio is a startup dedicated to developing cutting edge genetic therapies for muscle
diseases. In this proposal, the company will advance development of our potential therapeutic,
SPY-DYS45-55, a CRISPR/Cas9 gene editing platform for Duchenne muscular dystrophy (DMD)
in conjunction with research partners at UCLA. Duchenne is a devastating muscle wasting
disorder with no cure that is caused by out-of-frame mutations in the DMD gene. SPY-DYS45-55
removes a mutational hotspot in DMD to restore the reading frame for half of all Duchenne
patients by generating an in-frame exon 45-55 deletion. This deletion is associated with a very
mild phenotype in human Becker muscular dystrophy patients. Systemic delivery of gene editing
platforms to muscle represents a significant challenge. Certain serotypes of recombinant adenoassociated
virus (AAV) have tropism to skeletal muscle and heart. However, the immune
response to the virus prohibits repeated administration of AAV. Furthermore, pre-existing
immunity in some individuals (anticipated to be present in up to 70% of adults), precludes their
eligibility to take advantage of this treatment. The goal of this Fast Track proposal is to devise
strategies to overcome these challenges. In Phase I, we will determine an optimal
immunosuppression regimen that allows redosing of AAV in order to improve the efficacy and
applicability of SPY-DYS45-55. In Phase II, we will assess the long-term functional benefit,
toxicity, and off-target activity from single or multiple injections of AAV-SPY-DYS45-55 in our novel
mouse model containing a mutated human DMD gene. Ultimately, these studies will generate
the initial pre-clinical data needed to translate SPY-DYS45-55 to patients with Duchenne muscular

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government